Als Therapy Development Foundation Inc
- Assets
- $20.0m
- Revenue
- $11.6m
- Investments
- $0.0
- Employees
- 63
- Location
- Watertown, MA
- Founding
- 07/1999
- Data as of
- 12/2023
- EIN
- 04-3462719
Organization Overview
Als Therapy Development Foundation Inc, operating under the name Als Therapy Development Institute, is located in Watertown, MA. The organization was established in 1999. According to its NTEE Classification (H80) the organization is classified as: Specifically Named Diseases Research, under the broad grouping of Medical Research and related organizations. As of 12/2023, Als Therapy Development Institute employed 63 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Als Therapy Development Institute is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2023, Als Therapy Development Institute generated $11.6m in total revenue. The organization has seen a slow decline revenue. Over the past 8 years, revenues have fallen by an average of (0.3%) each year. All expenses for the organization totaled $11.2m during the year ending 12/2023. As we would expect to see with falling revenues, expenses have declined by (0.1%) per year over the past 8 years. You can explore the organizations financials more deeply in the financial statements section below.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2023
Describe the Organization's Mission:
Part 3 - Line 1
WE ARE COMMITTED TO CREATING AND LEADING A TRANSPARENT COLLABORATIVE RESEARCH PROCESS THAT INVOLVES ALS PATIENTS TODAY AND HONORS THOSE WHOSE JOURNEY WITH THIS DISEASE HAS ENDED. WE ARE GUIDED BY PASSION, LOVE AND THE SPIRIT OF ENTREPRENEURSHIP UPON WHICH WE WERE FOUNDED.
Describe the Organization's Program Activity:
Part 3 - Line 4a
ALS TDI COMBINES THE PASSION AND DEDICATION OF A NONPROFIT ORGANIZATION WITH THE ENTREPRENEURIAL AND SCIENTIFIC SPIRIT OF A BIOTECHNOLOGY COMPANY. OUR LABORATORY IS THE LEADING DRUG DISCOVERY PROGRAM FOR ALS, AND IT BRIDGES A CRITICAL RESEARCH GAP. OUR IN-HOUSE EXPERTISE TRANSLATES RESEARCH INTO POTENTIAL DRUG CANDIDATES BY SCREENING DRUGS IN THE SOD1 MOUSE MODEL OF ALS. OUR SCIENTIFIC COLLABORATIONS ARE DESIGNED TO BRING THE MOST PROMISING LEADS CLOSER TO PATIENT USE. WE SHARE EMERGING KNOWLEDGE ON THE DISEASE WITH PATIENTS, PHYSICIANS, AND RESEARCHERS AS QUICKLY AND COMPREHENSIVELY AS POSSIBLE. EVERY DECISION IS MADE IN THE INTEREST OF FINDING EFFECTIVE TREATMENTS FOR PEOPLE LIVING WITH ALS. OUR UNIQUE APPROACH ACCELERATES DRUG DEVELOPMENT FOR ALS.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Fernando Vieira CEO And Cso | OfficerTrustee | 40 | $320,000 |
Alan Gill VP Of Research | 40 | $182,421 | |
Carol Hamilton VP Of Development | 40 | $165,724 | |
Theo Hatzipetros Director Of Pharmacology | 40 | $150,899 | |
Kyle R Denton Director, Cell Biology | 40 | $150,194 | |
Kenneth Thompson VP Of Facility Operation | 40 | $129,202 |
Outside Vendors & Contractors
| Vendor Name (Service) | Service Year | Compensation |
|---|---|---|
Insource Services Inc Finance, Hr & It | 12/30/23 | $556,808 |
Unite Genomics Inc Research Consultant | 12/30/23 | $116,000 |
Somalogic Operating Co Inc Research Consultant | 12/30/23 | $110,000 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $5,194,033 |
| Related organizations | $0 |
| Government grants | $0 |
| All other contributions, gifts, grants, and similar amounts not included above | $4,835,541 |
| Noncash contributions included in lines 1a–1f | $260,590 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $10,029,574 |
| Total Program Service Revenue | $657,980 |
| Investment income | $363,770 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | $0 |
| Net Income from Fundraising Events | $503,577 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $11,558,482 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $0 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $0 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $340,011 |
| Compensation of current officers, directors, key employees. | $34,001 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $3,753,298 |
| Pension plan accruals and contributions | $38,088 |
| Other employee benefits | $528,763 |
| Payroll taxes | $307,984 |
| Fees for services: Management | $0 |
| Fees for services: Legal | $103,456 |
| Fees for services: Accounting | $51,334 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $27,160 |
| Fees for services: Investment Management | $0 |
| Fees for services: Other | $639,135 |
| Advertising and promotion | $61,856 |
| Office expenses | $149,050 |
| Information technology | $608,631 |
| Royalties | $0 |
| Occupancy | $1,673,353 |
| Travel | $5,638 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $119,580 |
| Interest | $14,228 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $186,568 |
| Insurance | $107,539 |
| All other expenses | $54,751 |
| Total functional expenses | $11,160,593 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $282,198 |
| Savings and temporary cash investments | $6,415,329 |
| Pledges and grants receivable | $455,824 |
| Accounts receivable, net | $97,420 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $297,565 |
| Net Land, buildings, and equipment | $393,002 |
| Investments—publicly traded securities | $7,976,815 |
| Investments—other securities | $0 |
| Investments—program-related | $0 |
| Intangible assets | $875,678 |
| Other assets | $3,218,820 |
| Total assets | $20,012,651 |
| Accounts payable and accrued expenses | $426,183 |
| Grants payable | $0 |
| Deferred revenue | $153,454 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $4,422,082 |
| Total liabilities | $5,001,719 |
| Net assets without donor restrictions | $14,810,932 |
| Net assets with donor restrictions | $200,000 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $20,012,651 |